Vyndaqel (tafamidis meglumine) | Friends of Cancer Research

You are here

Vyndaqel (tafamidis meglumine)

Sponsor: 
Pfizer Inc.
Indication: 
Patients with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)
Category: 
Year: 
2018
Date: 
May 24th
FDA Status: 
FDA Approval
Approval Date: 
May 6th
Approval Year: 
2019